MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina. The company was founded in 2003 and is headquartered in Montréal, Canada.

$5.52
As of 06/11/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  05/08/2019
Outstanding shares:  29,846,000
Average volume:  62,732
Market cap:   $163,108,390
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.02
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy